CONCORDBIO1,445.20

Concord Biotech Ltd.

· Pharma & Health
₹ CrorePeersBIOCONDIVISLABCAPLIPOINTEMCUREBLUEJETERISGRANULESACUTAASMcap ₹15,119 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt6.20.40.00.0
Net Debt-252.6-317.1-414.2-414.2
Net Debt/Equity-0.17-0.17-0.21-0.21
Total Debt/EBITDA0.010.000.000.00
Net Debt/EBITDA-0.59-0.63-1.13-1.07
Interest Coverage (EBIT/Interest)148.11853.881,034.401,034.40
Total Debt/Total Capital %0.410.020.000.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.